Ganitumab Explained

Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1] [2]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[3] [4]

Notes and References

  1. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab. American MedicaAssociation.
  2. Martínez P, Sales Fidalgo PA, Felip E . Ganitumab for the treatment of small-cell lung cancer . Expert Opinion on Investigational Drugs . 23 . 10 . 1423–32 . October 2014 . 25189625 . 10.1517/13543784.2014.951434 . 7318164 .
  3. News: Amgen Pulls Cancer Drug . 10 Aug 2012 . dead . https://web.archive.org/web/20130723163332/http://news.sciencemag.org/scienceinsider/2012/08/amgen-pulls-cancer-drug.html?ref=em . 2013-07-23 .
  4. News: Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial . 8 Aug 2012 . dead . https://web.archive.org/web/20120810222244/http://www.istockanalyst.com/finance/story/5984012/amgen-amgn-terminates-ganitumab-pancreatic-cancer-trial . 2012-08-10 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ganitumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.